$0.47
0.48% today
Nasdaq, Apr 01, 07:16 pm CET
ISIN
US15673T1007
Symbol
IPSC

Century Therapeutics Inc Stock price

$0.48
-0.21 30.29% 1M
-1.23 72.16% 6M
-0.53 52.87% YTD
-3.57 88.25% 1Y
-12.11 96.22% 3Y
-22.35 97.92% 5Y
-22.35 97.92% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.04 7.19%
ISIN
US15673T1007
Symbol
IPSC
Sector
Industry

Key metrics

Market capitalization $40.96m
Enterprise Value $-94.50m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.86
EV/Sales (TTM) EV/Sales -14.34
P/S ratio (TTM) P/S ratio 6.22
P/B ratio (TTM) P/B ratio 0.25
Revenue growth (TTM) Revenue growth 194.85%
Revenue (TTM) Revenue $6.59m
EBIT (operating result TTM) EBIT $-135.17m
Free Cash Flow (TTM) Free Cash Flow $-110.29m
Cash position $189.29m
EPS (TTM) EPS $-1.62
P/E forward negative
P/S forward 1.07
EV/Sales forward negative
Short interest 4.79%
Show more

Is Century Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Century Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Century Therapeutics Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Century Therapeutics Inc forecast:

Buy
88%
Hold
13%

Financial data from Century Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
6.59 6.59
194% 194%
100%
- Direct Costs 13 13
34% 34%
202%
-6.71 -6.71
13% 13%
-102%
- Selling and Administrative Expenses 21 21
43% 43%
322%
- Research and Development Expense 94 94
1% 1%
1,425%
-122 -122
6% 6%
-1,849%
- Depreciation and Amortization 13 13
34% 34%
202%
EBIT (Operating Income) EBIT -135 -135
8% 8%
-2,051%
Net Profit -127 -127
7% 7%
-1,921%

In millions USD.

Don't miss a Thing! We will send you all news about Century Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Century Therapeutics Inc Stock News

Neutral
GlobeNewsWire
13 days ago
PHILADELPHIA, March 19, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today reported financial results and business highlights for the full year 2024.
Neutral
GlobeNewsWire
4 months ago
PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that members of the management team will participate in the following events at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, ...
Neutral
GlobeNewsWire
5 months ago
– Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy –
More Century Therapeutics Inc News

Company Profile

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It engages in harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Head office United States
CEO Brent Pfeiffenberger
Employees 150
Founded 2018
Website www.centurytx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today